Cargando…
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621051/ https://www.ncbi.nlm.nih.gov/pubmed/36284469 http://dx.doi.org/10.1080/19420862.2022.2135183 |
_version_ | 1784821452531302400 |
---|---|
author | Hecht, Elizabeth Sara Mehta, Shrenik Wecksler, Aaron T. Aguilar, Ben Swanson, Nathaniel Phung, Wilson Dubey Kelsoe, Ananya Benner, W. Henry Tesar, Devin Kelley, Robert F. Sandoval, Wendy Sreedhara, Alavattam |
author_facet | Hecht, Elizabeth Sara Mehta, Shrenik Wecksler, Aaron T. Aguilar, Ben Swanson, Nathaniel Phung, Wilson Dubey Kelsoe, Ananya Benner, W. Henry Tesar, Devin Kelley, Robert F. Sandoval, Wendy Sreedhara, Alavattam |
author_sort | Hecht, Elizabeth Sara |
collection | PubMed |
description | Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that weak lipase–mAb interactions enable HCP lipases to evade drug purification processes. Here, we apply state-of-the-art methods to establish lipase-mAb binding mechanisms. First, the mass spectrometry (MS) approach of fast photochemical oxidation of proteins was used to elucidate putative binding regions. The CH1 domain was identified as a conserved interaction site for IgG1 and IgG4 mAbs against the HCPs phospholipase B-like protein (PLBL2) and lysosomal phospholipase A2 (LPLA2). Rationally designed mutations in the CH1 domain of the IgG4 mAb caused a 3- to 70-fold K(D) reduction against PLBL2 by surface plasmon resonance (SPR). LPLA2-IgG4 mutant complexes, undetected by SPR and studied using native MS collisional dissociation experiments, also showed significant complex disruption, from 16% to 100%. Native MS and ion mobility (IM) determined complex stoichiometries for four lipase-IgG4 complexes and directly interrogated the enrichment of specific lipase glycoforms. Confirmed with time-course and exoglycosidase experiments, deglycosylated lipases prevented binding, and low-molecular-weight glycoforms promoted binding, to mAbs. This work demonstrates the value of integrated biophysical approaches to characterize micromolar affinity complexes. It is the first in-depth structural report of lipase-mAb binding, finding roles for the CH1 domain and lipase glycosylation in mediating binding. The structural insights gained offer new approaches for the bioengineering of cells or mAbs to reduce HCP impurity levels. Abbreviations: CAN, Acetonitrile; AMAC, Ammonium acetate; BFGS, Broyden–Fletcher–Goldfarb–Shanno; CHO, Chinese Hamster Ovary; K(D), Dissociation constant; DTT, Dithiothreitol; ELISA, Enzyme-linked immunosorbent assay; FPOP, Fast photochemical oxidation of proteins; FA, Formic acid; F(ab’), Fragment antibodies; HCP, Host cell protein; IgG, Immunoglobulin; IM, Ion mobility; LOD, Lower limit of detection; LPLA2, Lysosomal phospholipase A2; Man, Mannose; MS, Mass spectrometry; MeOH, Methanol; MST, Microscale thermophoresis; mAbs, Monoclonal antibodies; PPT1, Palmitoyl protein thioesterase; ppm, Parts per million; PLBL2, Phospholipase B-like protein; PLD3, Phospholipase D3; PS-20, Polysorbate-20; SP, Sphingomyelin phosphodiesterase; SPR, Surface plasmon resonance; TFA, Trifluoroacetic acid. |
format | Online Article Text |
id | pubmed-9621051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-96210512023-02-07 Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms Hecht, Elizabeth Sara Mehta, Shrenik Wecksler, Aaron T. Aguilar, Ben Swanson, Nathaniel Phung, Wilson Dubey Kelsoe, Ananya Benner, W. Henry Tesar, Devin Kelley, Robert F. Sandoval, Wendy Sreedhara, Alavattam MAbs Report Detection of host cell protein (HCP) impurities is critical to ensuring that recombinant drug products, including monoclonal antibodies (mAbs), are safe. Mechanistic characterization as to how HCPs persist in drug products is important to refining downstream processing. It has been hypothesized that weak lipase–mAb interactions enable HCP lipases to evade drug purification processes. Here, we apply state-of-the-art methods to establish lipase-mAb binding mechanisms. First, the mass spectrometry (MS) approach of fast photochemical oxidation of proteins was used to elucidate putative binding regions. The CH1 domain was identified as a conserved interaction site for IgG1 and IgG4 mAbs against the HCPs phospholipase B-like protein (PLBL2) and lysosomal phospholipase A2 (LPLA2). Rationally designed mutations in the CH1 domain of the IgG4 mAb caused a 3- to 70-fold K(D) reduction against PLBL2 by surface plasmon resonance (SPR). LPLA2-IgG4 mutant complexes, undetected by SPR and studied using native MS collisional dissociation experiments, also showed significant complex disruption, from 16% to 100%. Native MS and ion mobility (IM) determined complex stoichiometries for four lipase-IgG4 complexes and directly interrogated the enrichment of specific lipase glycoforms. Confirmed with time-course and exoglycosidase experiments, deglycosylated lipases prevented binding, and low-molecular-weight glycoforms promoted binding, to mAbs. This work demonstrates the value of integrated biophysical approaches to characterize micromolar affinity complexes. It is the first in-depth structural report of lipase-mAb binding, finding roles for the CH1 domain and lipase glycosylation in mediating binding. The structural insights gained offer new approaches for the bioengineering of cells or mAbs to reduce HCP impurity levels. Abbreviations: CAN, Acetonitrile; AMAC, Ammonium acetate; BFGS, Broyden–Fletcher–Goldfarb–Shanno; CHO, Chinese Hamster Ovary; K(D), Dissociation constant; DTT, Dithiothreitol; ELISA, Enzyme-linked immunosorbent assay; FPOP, Fast photochemical oxidation of proteins; FA, Formic acid; F(ab’), Fragment antibodies; HCP, Host cell protein; IgG, Immunoglobulin; IM, Ion mobility; LOD, Lower limit of detection; LPLA2, Lysosomal phospholipase A2; Man, Mannose; MS, Mass spectrometry; MeOH, Methanol; MST, Microscale thermophoresis; mAbs, Monoclonal antibodies; PPT1, Palmitoyl protein thioesterase; ppm, Parts per million; PLBL2, Phospholipase B-like protein; PLD3, Phospholipase D3; PS-20, Polysorbate-20; SP, Sphingomyelin phosphodiesterase; SPR, Surface plasmon resonance; TFA, Trifluoroacetic acid. Taylor & Francis 2022-10-25 /pmc/articles/PMC9621051/ /pubmed/36284469 http://dx.doi.org/10.1080/19420862.2022.2135183 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Hecht, Elizabeth Sara Mehta, Shrenik Wecksler, Aaron T. Aguilar, Ben Swanson, Nathaniel Phung, Wilson Dubey Kelsoe, Ananya Benner, W. Henry Tesar, Devin Kelley, Robert F. Sandoval, Wendy Sreedhara, Alavattam Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title | Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title_full | Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title_fullStr | Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title_full_unstemmed | Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title_short | Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
title_sort | insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621051/ https://www.ncbi.nlm.nih.gov/pubmed/36284469 http://dx.doi.org/10.1080/19420862.2022.2135183 |
work_keys_str_mv | AT hechtelizabethsara insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT mehtashrenik insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT wecksleraaront insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT aguilarben insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT swansonnathaniel insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT phungwilson insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT dubeykelsoeananya insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT bennerwhenry insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT tesardevin insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT kelleyrobertf insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT sandovalwendy insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms AT sreedharaalavattam insightsintoultralowaffinitylipaseantibodynoncovalentcomplexbindingmechanisms |